BR0306798A - Uso de melagatran ou de um derivado farmaceuticamente aceitável deste, métodos de tratamento de diabetes mellitus tipo i, de transplante de células de enxertamento de ilhotas de langerhans, para melhorar a independência de insulina em pacientes com diabetes mellitus tipo i, e de tratamento de reação inflamatória mediada pelo sangue instantânea, formulação farmacêutica para uso no tratamento de diabetes mellitus tipo i, kit de partes, e, método de fabricação de um kit de partes. - Google Patents
Uso de melagatran ou de um derivado farmaceuticamente aceitável deste, métodos de tratamento de diabetes mellitus tipo i, de transplante de células de enxertamento de ilhotas de langerhans, para melhorar a independência de insulina em pacientes com diabetes mellitus tipo i, e de tratamento de reação inflamatória mediada pelo sangue instantânea, formulação farmacêutica para uso no tratamento de diabetes mellitus tipo i, kit de partes, e, método de fabricação de um kit de partes.Info
- Publication number
- BR0306798A BR0306798A BR0306798-0A BR0306798A BR0306798A BR 0306798 A BR0306798 A BR 0306798A BR 0306798 A BR0306798 A BR 0306798A BR 0306798 A BR0306798 A BR 0306798A
- Authority
- BR
- Brazil
- Prior art keywords
- diabetes mellitus
- type
- parts kit
- treatment
- melagatran
- Prior art date
Links
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 title abstract 4
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- DKWNMCUOEDMMIN-PKOBYXMFSA-N melagatran Chemical compound C1=CC(C(=N)N)=CC=C1CNC(=O)[C@H]1N(C(=O)[C@H](NCC(O)=O)C2CCCCC2)CC1 DKWNMCUOEDMMIN-PKOBYXMFSA-N 0.000 title abstract 3
- 229960002137 melagatran Drugs 0.000 title abstract 3
- 239000008280 blood Substances 0.000 title abstract 2
- 210000004369 blood Anatomy 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 210000004153 islets of langerhan Anatomy 0.000 title abstract 2
- 230000001404 mediated effect Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 2
- 102000004877 Insulin Human genes 0.000 title 1
- 108090001061 Insulin Proteins 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 230000002757 inflammatory effect Effects 0.000 title 1
- 229940125396 insulin Drugs 0.000 title 1
- 238000002054 transplantation Methods 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 238000010413 gardening Methods 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/39—Pancreas; Islets of Langerhans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Physiology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0200198A SE0200198D0 (sv) | 2002-01-23 | 2002-01-23 | New use |
| PCT/SE2003/000087 WO2003061682A1 (en) | 2002-01-23 | 2003-01-21 | The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0306798A true BR0306798A (pt) | 2004-12-07 |
Family
ID=20286751
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0306798-0A BR0306798A (pt) | 2002-01-23 | 2003-01-21 | Uso de melagatran ou de um derivado farmaceuticamente aceitável deste, métodos de tratamento de diabetes mellitus tipo i, de transplante de células de enxertamento de ilhotas de langerhans, para melhorar a independência de insulina em pacientes com diabetes mellitus tipo i, e de tratamento de reação inflamatória mediada pelo sangue instantânea, formulação farmacêutica para uso no tratamento de diabetes mellitus tipo i, kit de partes, e, método de fabricação de um kit de partes. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7045502B2 (OSRAM) |
| EP (1) | EP1469874A1 (OSRAM) |
| JP (1) | JP2005516035A (OSRAM) |
| KR (1) | KR20040075096A (OSRAM) |
| CN (1) | CN100430089C (OSRAM) |
| BR (1) | BR0306798A (OSRAM) |
| CA (1) | CA2472241A1 (OSRAM) |
| IL (1) | IL162853A0 (OSRAM) |
| MX (1) | MXPA04007192A (OSRAM) |
| NO (1) | NO20043483L (OSRAM) |
| NZ (1) | NZ533749A (OSRAM) |
| SE (1) | SE0200198D0 (OSRAM) |
| WO (1) | WO2003061682A1 (OSRAM) |
| ZA (1) | ZA200405342B (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0200198D0 (sv) * | 2002-01-23 | 2002-01-23 | Astrazeneca Ab | New use |
| JP6155187B2 (ja) | 2010-03-30 | 2017-06-28 | ヴァーセオン コーポレイション | トロンビンの阻害剤としての多置換芳香族化合物 |
| WO2014145986A1 (en) | 2013-03-15 | 2014-09-18 | Verseon, Inc. | Multisubstituted aromatic compounds as serine protease inhibitors |
| ES2791749T3 (es) | 2013-03-15 | 2020-11-05 | Verseon Corp | Halogenopirazoles como inhibidores de la trombina |
| KR20170048410A (ko) | 2014-09-17 | 2017-05-08 | 베르선 코포레이션 | 세린 프로테아제 저해제로서의 피라졸릴-치환된 피리돈 화합물 |
| AU2016224974B2 (en) | 2015-02-27 | 2019-09-26 | Verseon Corporation | Substituted pyrazole compounds as serine protease inhibitors |
| IL280078B2 (en) | 2018-07-13 | 2024-04-01 | Verseon Int Corporation | Thrombin inhibitors, formulations, and uses thereof |
| AU2022325955A1 (en) | 2021-08-11 | 2024-02-08 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions |
| JP2025508720A (ja) | 2022-02-17 | 2025-04-10 | サナ バイオテクノロジー，インコーポレイテッド | 遺伝子操作されたｃｄ４７タンパク質及びその使用関連出願の相互参照 |
| AU2024264889A1 (en) | 2023-05-03 | 2025-11-13 | Sana Biotechnology, Inc. | Methods of dosing and administration of engineered islet cells |
| CN121604968A (zh) | 2023-05-22 | 2026-03-03 | 萨那生物科技公司 | 递送胰岛细胞的方法及相关方法 |
| IL326710A (en) | 2023-08-23 | 2026-04-01 | Sana Biotechnology Inc | Modified CD47 proteins and their uses |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9301916D0 (sv) | 1993-06-03 | 1993-06-03 | Ab Astra | New peptides derivatives |
| TW541316B (en) | 1995-12-21 | 2003-07-11 | Astrazeneca Ab | Prodrugs of thrombin inhibitors |
| SE9900070D0 (sv) | 1999-01-13 | 1999-01-13 | Astra Ab | New use |
| SE523817C2 (sv) | 1999-02-05 | 2004-05-18 | Corline Systems Ab | Användning av ett koagulationsförebyggande ämne i samband med transplantation av insulinproducerande celler |
| US6462021B1 (en) | 2000-11-06 | 2002-10-08 | Astrazeneca Ab | Use of low molecular weight thrombin inhibitor |
| SE0200198D0 (sv) * | 2002-01-23 | 2002-01-23 | Astrazeneca Ab | New use |
-
2002
- 2002-01-23 SE SE0200198A patent/SE0200198D0/xx unknown
-
2003
- 2003-01-21 MX MXPA04007192A patent/MXPA04007192A/es unknown
- 2003-01-21 EP EP03701203A patent/EP1469874A1/en not_active Withdrawn
- 2003-01-21 JP JP2003561625A patent/JP2005516035A/ja active Pending
- 2003-01-21 CN CNB038026740A patent/CN100430089C/zh not_active Expired - Fee Related
- 2003-01-21 IL IL16285303A patent/IL162853A0/xx unknown
- 2003-01-21 BR BR0306798-0A patent/BR0306798A/pt not_active IP Right Cessation
- 2003-01-21 NZ NZ533749A patent/NZ533749A/en unknown
- 2003-01-21 US US10/502,069 patent/US7045502B2/en not_active Expired - Fee Related
- 2003-01-21 WO PCT/SE2003/000087 patent/WO2003061682A1/en not_active Ceased
- 2003-01-21 KR KR10-2004-7011228A patent/KR20040075096A/ko not_active Withdrawn
- 2003-01-21 CA CA002472241A patent/CA2472241A1/en not_active Abandoned
-
2004
- 2004-07-05 ZA ZA2004/05342A patent/ZA200405342B/en unknown
- 2004-08-20 NO NO20043483A patent/NO20043483L/no not_active Application Discontinuation
-
2006
- 2006-02-24 US US11/362,890 patent/US20060148720A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20060148720A1 (en) | 2006-07-06 |
| US7045502B2 (en) | 2006-05-16 |
| US20050090424A1 (en) | 2005-04-28 |
| ZA200405342B (en) | 2005-09-28 |
| IL162853A0 (en) | 2005-11-20 |
| CN1729010A (zh) | 2006-02-01 |
| SE0200198D0 (sv) | 2002-01-23 |
| NZ533749A (en) | 2006-02-24 |
| KR20040075096A (ko) | 2004-08-26 |
| WO2003061682A1 (en) | 2003-07-31 |
| CA2472241A1 (en) | 2003-07-31 |
| CN100430089C (zh) | 2008-11-05 |
| JP2005516035A (ja) | 2005-06-02 |
| EP1469874A1 (en) | 2004-10-27 |
| MXPA04007192A (es) | 2004-10-29 |
| NO20043483L (no) | 2004-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1111159T1 (el) | Πυκνα διαλυματα μεθοτρεξατης | |
| BG106095A (bg) | Нови лекарствени състави на базата на антихолинергично активни съединения и бета-миметици | |
| GB0211649D0 (en) | Organic compounds | |
| MY142551A (en) | Substituted diaryl heterocycles, process for their preparation and their use as medicaments | |
| CU23208A3 (es) | Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea | |
| NO20043871L (no) | Legemiddelformuleringer med kontrollert frigjoring som inneholder et baererpeptid | |
| NO20060981L (no) | Pyridazinderivater og deres anvendelse som terapeutiske midler | |
| EA200501420A1 (ru) | Устройство доставки для лекарственной и клеточной терапии | |
| BR9906813A (pt) | Método para administração de insulina aspb28- humana | |
| BR0308196A (pt) | Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com a glicogênio sintase cinase-3, e de doenças, e, processo para a preparação de um composto | |
| NO20070576L (no) | Nye hydantionderivater for behandling av obstruktive luftveissykdommer. | |
| HRP20130406T1 (hr) | Medikamenti s aktivnošä†u prema receptoru hm74a | |
| CY1114863T1 (el) | Στερεο παρασκευασμα | |
| NO20061859L (no) | OROS Push Stick for kontrollert tilforsel av aktive midler | |
| MX2007000028A (es) | Derivados de nicotinamida y su uso como agentes terapeuticos. | |
| ATE493981T1 (de) | Einmal tägliche dosierformen von trospium | |
| PE20011074A1 (es) | Uso de pramipexol en el tratamiento de trastornos de adiccion | |
| NO20050569L (no) | Fremgangsmate for behandling av alvorlig hjertesvikt og medikament for dette | |
| WO2005016867A3 (en) | Anthranilic acid derivatives and their use as activators of the hm74a receptor | |
| BRPI0411503A (pt) | composto, composição farmacêutica, uso de um composto, método de tratar um ser humano que sofre de uma doença hiperproliferativa tal como cáncer, e, processo para a preparação de um composto | |
| BR0212249A (pt) | Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto | |
| SE9900398D0 (sv) | Novel use within transplantation surgery | |
| AR036591A1 (es) | Uso de la hl en hiperestimulacion ovarica controlada | |
| WO2004071398A3 (en) | Pharmaceutical patch | |
| WO2003072019A3 (en) | Sequential therapy comprising a 20(s)-camptothecin compound and a pyrimidine base analog |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A(S) 7A E 8A ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2112 DE 28/06/2011. |